1-3 of 3
Anne Verhagen
Close
Sort by
Journal Articles

A Quantitative Systems Pharmacology (QSP) Model to Compare the Non-Clinical Biodistribution and Efficacy between Recombinant Factor IX (rIX) Therapies

Sabine Pestel, Douglas Chung, Alireza Rezvani-Sharif, Ineke Muir, Sivarmurthy Krupa, Markus Brechmann, Anne Verhagen, Steve Dower, Piet H. van der Graaf, Eva Herzog, Oliver Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 4240.
https://doi.org/10.1182/blood-2021-145878
Published: 2021
Journal Articles

Profiling and Comparing the Immunogenicity of a Novel Single-Chain FVIII Molecule (rVIII-SingleChain) for the Treatment of Hemophilia a

Eugene Maraskovsky, PhD, Anne Verhagen, PhD, Huy Huynh, BS, Adriana Baz Morelli, PhD, Stefan Schmidbauer, BS, Sabine Zollner, PhD, Jerry S. Powell, Katie St Ledger, Alex Veldman, MD, Marco Hofmann, MS
Journal: Blood
Blood (2016) 128 (22): 4960.
https://doi.org/10.1182/blood.V128.22.4960.4960
Published: 2016
Journal Articles

Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma

Paul G. Ekert, Anissa M. Jabbour, Anand Manoharan, Jacki E. Heraud, Jai Yu, Miha Pakusch, Ewa M. Michalak, Priscilla N. Kelly, Bernard Callus, Thomas Kiefer, Anne Verhagen, John Silke, Andreas Strasser, Christoph Borner, David L. Vaux
Journal: Blood
Blood (2006) 108 (5): 1461–1468.
https://doi.org/10.1182/blood-2006-03-014209
Published: 2006
Includes: Supplemental data